Physician profile
Corwin D Petty
NPI 1295735959
$3,333.15
in general payments reported to CMS, 2019-2025
28 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.22 · 2020: $481 · 2021: $648 · 2022: $454 · 2023: $882 · 2024: $380 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.98 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $417.36 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $390.29 | 2020-2023 | Farxiga |
| Currax Pharmaceuticals LLC | $378.70 | 2020-2025 | Contrave, Onzetra Xsail, Nexletol |
| Novo Nordisk INC | $335.14 | 2019-2022 | |
| Pfizer INC. | $261.16 | 2024-2025 | |
| Abbvie INC. | $219.49 | 2021-2023 | |
| Lilly USA, LLC | $196.47 | 2020-2021 | |
| Abbott Laboratories | $147.03 | 2022-2024 | Freestyle Libre 3 |
| Eisai INC. | $139.85 | 2020-2021 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $105.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $82.17 | 2020-2023 | Belsomra, Steglatro |
| Supernus Pharmaceuticals, INC. | $66.12 | 2019-2020 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $64.87 | 2020-2021 | |
| Antares Pharma, INC. | $54.18 | 2023 | Xyosted, Tlando, Nocdurna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $52.05 | 2023-2025 | Adthyza, Azmiro |
| Acella Pharmaceuticals, LLC | $48.33 | 2023-2024 | NP Thyroid 60 |
| Ironshore Pharmaceuticals INC. | $42.73 | 2023 | Jornay Pm |
| Halozyme INC | $36.44 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.35 | 2021 | |
| Allergan, INC. | $24.11 | 2020 | |
| Amarin Pharma, INC. | $19.92 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.00 | 2025 | Zoryve |
| Gilead Sciences, INC. | $16.21 | 2020 | |
| Ibsa Pharma INC. | $14.00 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $13.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corwin Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.